8-K: TuHURA Biosciences Appoints New Auditor Following Merger, Dismisses Marcum LLP

TuHURA Biosciences, formerly Kintara Therapeutics, has appointed Cherry Bekaert LLP as its new independent auditor, replacing Marcum LLP, following the completion of a merger.

Summary

• TuHURA Biosciences, previously known as Kintara Therapeutics, completed a merger on December 27, 2024.
• As a result of the merger, Marcum LLP was dismissed as the company's independent registered public accounting firm on December 31, 2024.
• The decision to dismiss Marcum was approved by the Audit Committee on December 27, 2024.
• Cherry Bekaert LLP, who previously served as the auditor for TuHURA Delaware, was appointed as the new independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Marcum's reports on Kintara's financials for the fiscal years ended June 30, 2024 and 2023 did not contain any adverse opinions, though they did include an explanatory paragraph about the company's ability to continue as a going concern.
• There were no disagreements between Kintara and Marcum on accounting principles or auditing scope.
• TuHURA Delaware did not consult with Cherry Bekaert on any matters requiring disclosure.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive. The change in auditors is expected after a merger, and there are no indications of any issues with the transition. However, the going concern note in the previous auditor's report is a slight concern.

Positives

• The transition to a new auditor appears to be smooth, with no reported disagreements or issues.
• The company has quickly appointed a new auditor following the merger.

Negatives

• Marcum's audit reports included an explanatory paragraph about Kintara's ability to continue as a going concern, which could be a concern for investors.

Risks

• The change in auditors could potentially lead to increased scrutiny of the company's financials.
• The going concern note in Marcum's report could raise concerns about the company's financial stability.

Management Comments

• The Audit Committee unanimously approved the dismissal of Marcum and the appointment of Cherry Bekaert.

Industry Context

Changes in auditors are common after mergers and acquisitions, as the newly formed entity often consolidates its financial reporting under a single firm.

Comparison to Industry Standards

• The process of changing auditors after a merger is standard practice in the industry.
• Many companies switch auditors to align with the new corporate structure and to ensure a fresh perspective on financial reporting.
• The lack of disagreements with the previous auditor is a positive sign, indicating a smooth transition.

Stakeholder Impact

• Shareholders may be interested in the change of auditors and the implications for financial reporting.
• Employees may be affected by the merger and the resulting changes in the company's structure.

Key Dates

Keywords

merger, auditor, accounting, financial statements, Marcum LLP, Cherry Bekaert LLP, TuHURA Biosciences, Kintara Therapeutics